Professor25/iStock via Getty Images
DBV Technologies (DBVT) climbed ~41% in the premarket on Wednesday after the French biotech announced that a Phase 3 trial for its Viaskin Peanut patch for children with peanut allergies reached its main goal.
Citing 12-month data, the company said that